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Abstract: Bisbenzylisoquinoline (BBIQ) alkaloids are a diverse group of natural products that 18 
demonstrate a range of biological activities. In this study, the in vitro antiplasmodial activity of three 19 
BBIQ alkaloids (cycleanine (1), isochondodendrine (2) and 2′-norcocsuline (3)) isolated from the 20 
Triclisia subcordata Oliv. medicinal plant traditionally used for the treatment of malaria in Nigeria are 21 
studied alongside two semi-synthetic analogues (4 and 5) of cycleanine. The antiproliferative effects 22 
against a chloroquine-resistant Plasmodium falciparum strain were determined using a SYBR Green 1 23 
fluorescence assay. The in vivo antimalarial activity of cycleanine (1) is then investigated in 24 
suppressive, prophylactic and curative murine malaria models after infection with a 25 
chloroquine-sensitive Plasmodium berghei strain. BBIQ alkaloids (1-5) exerted in vitro antiplasmodial 26 
activities with IC50 at low micromolar concentrations with the two semi-synthetic cycleanine 27 
analogues showing an improved potency and selectivity than cycleanine. At oral doses of 25 and 28 
50mg/kg body weight of infected mice, cycleanine suppressed the levels of parasitaemia, and 29 
increased mean survival times significantly compared to the control groups. The metabolites and 30 
metabolic pathways of cycleanine (1) were also studied using high performance liquid 31 
chromatography electrospray ionization tandem mass spectrometry. Twelve novel metabolites were 32 
detected in rats after intragastic administration of cycleanine. The metabolic pathways of cycleanine 33 
were demonstrated to involve hydroxylation, dehydrogenation, and demethylation. Overall, these 34 
in vitro and in vivo results provide a basis for the future evaluation of cycleanine and its analogues as 35 
leads for further development. 36 
Keywords: Malaria; Plasmodium falciparum; Plasmodium berghei; bisbenzylisoquinoline alkaloids; 37 
cycleanine; metabolism; in vivo activity. 38 
 39 
40 
 
 
2 
1. Introduction 41 
In 2018, the World Health Organization (WHO) report estimated a global burden of 228 million 42 
cases accounting for 405,000 deaths [1]. The majority of this burden fell on the WHO Africa Region, 43 
where malaria, particularly that caused by the most virulent etiological agent Plasmodium falciparum, 44 
exerts an immense economic impact. Whilst malaria cases and mortality figures continue to fall [1, 45 
2], the development and spread of resistance to available chemotherapeutic agents poses a 46 
significant threat to malaria treatment and management [3]. Natural products of plant origin have 47 
traditionally provided good sources for discovery of drug leads or novel compounds in modern 48 
drug research [4,5]. For example, artemisinin isolated from Artemisia annua, sweet wormwood, a 49 
traditional Chinese medicine, together with a series of its semi-synthetic derivatives, has become the 50 
first-line therapy for P. falciparum malaria [6,7]. However, due to the development of artemisinin 51 
drug resistance [8], novel therapies are still urgently needed. 52 
 53 
Bisbenzylisoquinoline (BBIQ) alkaloids are a diverse group of natural products consisting of 54 
two benzylisoquinoline groups [9]. BBIQ alkaloids are primarily found in the Berberidaceae, 55 
Lauraceae, Menispermaceae, and Ranunculaceae plant families. These alkaloids possess a variety of 56 
biological activities including antimalarial activities [9,10]. For example, BBIQ alkaloids isolated and 57 
identified from Triclisia species of the Menispermaceae family have antiproliferative activities [10]. In 58 
Nigeria, the root of Triclisia subcordata Oliv. is traditionally used for the treatment of a range of 59 
diseases, including malaria [11,12]. The bioactive components of T. subcordata are the BBIQ alkaloids 60 
cycleanine (1), isochondodendrine (2) and 2′-norcocsuline (3) (Figure 1) and have previously been 61 
isolated and characterized by our group[13,14]. We have also produced synthetic analogues of 62 
cycleanine (4 and 5) (Figure 1) [15]. The three naturally occurring BBIQ alkaloids, cycleanine [16-18], 63 
isochondodendrine [18,19], and 2′-norcocsuline [16,20] have been reported to possess antiplasmodial 64 
effects against chloroquine-sensitive and chloroquine-resistant P. falciparum strains. Despite the 65 
promising in vitro biological activity of these natural BBIQ alkaloids, the in vivo antimalarial activity 66 
of BBIQ alkaloids has not been evaluated nor their potential in vivo metabolism. Here we assess the 67 
in vivo antimalarial activity and metabolism of cycleanine (1). The effect of increasing the water 68 
solubility of cycleanine analogues (4 and 5) on antiplasmodial potency and selectivity will also be 69 
investigated.  70 
 71 
 72 
 73 
Figure 1. Chemical structure of bisbenzylisoquinoline (BBIQ) alkaloids. Cycleanine (1), 74 
isochondodendrine (2) and 2′-norcocsuline (3) from T. subcordata and two novel semi-synthetic 75 
analogues (4 and 5) of cycleanine.  76 
 77 
This study sets out an evaluation of the in vitro antimalarial activities of the BBIQ alkaloids (1-3) 78 
compared to two semi-synthetic BBIQ alkaloids (4 and 5) derived by a modification of cycleanine at 79 
the C-5 position by introducing additional secondary or tertiary amine moieties in an attempt to 80 
increase potential solubility and potency [15]. The most abundant BBIQ alkaloid in T. subcordata 81 
extract is cycleanine, this was therefore used to establish in vivo antimalarial activity in a murine 82 
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malaria model. In addition, the metabolites and metabolic pathways of cycleanine were analyzed 83 
after intragastric administration in rats to help understand how cycleanine is eliminated in vivo to 84 
guide future optimization of cycleanine for antimalarial development. 85 
2. Results 86 
2.1 The semi-synthetic derivatives of cycleanine have improved in vitro antiplasmodial 87 
activity and selectivity 88 
 89 
The in vitro antiplasmodial activity of the five BBIQ alkaloids (1-5) as well as a chloroquine 90 
control were performed against intraerythrocytic stages of the P. falciparum Dd2 chloroquine 91 
resistant strain using a Malaria SYBR Green I fluorescence assay. These data are provided in Table 1 92 
(Figure S1) as IC50 values (mean ± SD for n = 3 independent biological repeats). Whilst the data for 93 
chloroquine in Dd2 are comparable to that of the W2 chloroquine resistant strain, the activities of 94 
cycleanine, isochondodendrine and 2′-norcocsuline are significantly lower in Dd2 than reported in 95 
W2, and certainly lower than that in the chloroquine sensitive strain D6. The semi-synthetic products 96 
4 and 5 are relatively more potent than 1-3 in Dd2, with the most potent, 4, some 25.2-fold more 97 
potent than its natural precursor- cycleanine (1).  98 
Data from cytotoxicity studies of BBIQ alkaloids 1-3 in human oral epidermoid carcinoma (KB) 99 
or HCT-116 human colon carcinoma cells suggest low to moderate selectivity with SI of 14 to >133. 100 
CC50 data for all five compounds are available from human ovarian epithelial (HOE) cells (Table 1). 101 
These data reinforce the findings of low selectivity, albeit improved in the semi-synthetic products 4 102 
and 5.  103 
 104 
Table 1. The in-vitro half maximal inhibitory concentration (IC50) values of BBIQ alkaloids (1-5) 105 
against P. falciparum chloroquine resistant strains (Dd2 and W2 strain), chloroquine sensitive strain 106 
(D6), and the 50% cytotoxic concentration (CC50) values against cancer cell lines, and selectivity 107 
index (SI). 108 
 109 
BBIQ alkaloids  P. 
falciparu
m Dd2 
(µM) a 
P. 
falciparu
m W2 
(µM)b,c 
P. 
falcipar
um D6 
(µM)b ,d 
KBb or 
HCTc 
(µM)  
HOE 
(µM) e 
SI 
(KB/
W2) f 
SI 
(HOE/Dd
2) f 
Cycleanine (1) 17.7 ± 2.0 0.25b; 4.5 c 0.07 b >33.7b; 
531 
(HCT)c 
35.0 ± 0.1  >133 2.0 
Isochondodendrin
e (2) 
6.1 ± 1.3 0.2 c N.D. d 29 
(HCT)c 
10.5 ± 1.2  116 1.7 
2’-Norcocsuline (3) 7.0 ± 1.6 0.28b 0.048b 3.8b 8.0 ± 0.2  14 1.1 
5-[(Dimethylamin
o)methyl]cycleani
ne (4) 
0.7 ± 0.1 N.D. N.D. N.D. 10.0 ± 0.2  N.D. 14.3 
5-[(Propargylamin
o)methyl]cycleani
ne  (5) 
1.8 ± 0.2 N.D. N.D. N.D. 32.0 ± 1.6  N.D. 17.8 
Chloroquine 0.18 ± 
0.03 
0.135b 0.006b 33.7b N.D. 250 N.D. 
 110 
a IC50 values are expressed as mean ± SD for n = 3 independent biological repeats. 111 
b IC50 data against P. falciparum W2 and D6 strains, and CC50 for human oral epidermoid 112 
carcinoma (KB) cells were sourced from a previous report [16].  113 
c IC50 data against chloroquine resistant P. falciparum strain, and CC50 for HCT-116 human colon 114 
carcinoma cells were sourced from a previous report [18]. 115 
 
 
4 
d N.D., not determined. 116 
e CC50 data for human ovarian epithelial (HOE) cells. Data in this column for 1-5 were sourced 117 
from our previous reports [13,15]. 118 
f SI, this selectivity index was calculated as CC50 in cytotoxicity/IC50P. falciparum. 119 
 120 
2.2 In vivo antimalarial activity of cycleanine (1)  121 
The isolation of the abundant cycleanine (1) in T. subcordata root enabled us to investigate its 122 
efficacy and toxicity in murine malaria models after infection with Plasmodium berghei. The acute 123 
LD50 of cycleanine after 24h oral administration was determined to be 4.5 g/kg in mice, indicating a 124 
good safety profile. The malaria suppressive activity of cycleanine using two oral doses (25 and 50 125 
mg/kg of body weight/day) following P. berghei infection was demonstrated through a significant 126 
suppression of parasitaemia and increased mean survival time (MST) compared to untreated 127 
controls (Table 2). In particular, the higher dose (50 mg/kg/day) showed efficacy, both in terms of 128 
suppression of parasitaemia and MST, comparable to that for chloroquine at a dose of 5 mg/kg/day. 129 
The prophylactic activity of cycleanine, with the same 25 and 50 mg/kg dosing regimen during P. 130 
berghei infection in mice, was also demonstrated (Table 3). At the higher dose (50 mg/kg), cycleanine 131 
showed a suppression of parasitaemia by 59.0%, only slightly less than that of 76.2% using the 132 
prophylactic pyrimethamine control at a dose of 1.2 mg/kg /day.   133 
 134 
Table 2: Suppressive activity of cycleanine during early Plasmodium berghei infection of mice.   135 
 136 
Treatment Dose 
(mg/kg) 
per day 
Parasitaemia after 
infection for 96h (%)a 
Suppression of 
parasitaemia at 96h 
(%)a 
MST (days)a 
Untreated 
control 
- 28.3 ± 1.8 -  12.5 ± 0.3 
Cycleanine 25 15.7 ± 1.8 b 44.7 24.7 ± 1.1 b 
50 3.8 ± 0.7 b 86.5 28.2 ± 0.9 b 
Chloroquine 5  2.0 ± 0.8 b 94.0 30.0 ± 0.0 b 
 137 
a values are expressed as mean ± SEM (n = 6 in each group) 138 
b Significant relative to untreated control, p < 0.001. 139 
 140 
Table 3: Prophylactic activity of cycleanine in Plasmodium berghei infection of mice.  141 
 142 
a values are expressed as mean ± SEM (n = 6 in each group) 143 
b Significant relative to control, p < 0.001. 144 
 145 
Treatment Dose 
(mg/kg) 
per day 
Parasitaemia 
level after 
infection for 
72h (%)a 
Suppression of 
parasitaemia 
level after 
infection for 
72h (%)a 
MST (day)a 
Untreated control - 20.3 ± 0.8 - 12.7 ± 0.3 
Cycleanine 25 11.5 ± 0.9 b 43.4 23.0 ± 0.6 b 
50 7.3 ± 1.0 b 59.0 24.5 ± 0.6 b 
Pyrimethamine 1.2 4.8 ± 1.1 b 76.2 29.8 ± 0.2 b 
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The curative activity and MST of mice after initial P. berghei infection and subsequent treatment 146 
with cycleanine (1) were determined. After infection of mice for three days, cycleanine were 147 
administered at both doses of 25 and 50 mg/kg and showed decreasing parasitaemia in a 148 
dose-dependent and time-dependent manner from day 3 to day 7 (Fig. 2). The speed of killing P. 149 
berghei parasites by chloroquine was much faster than cycleanine. Chloroquine reached 0% of 150 
parasitaemia after 5 days, while at that time cycleanine at doses of 25 and 50 mg/kg had remaining 151 
levels of 13.3 and 10.5%, respectively (Figure 2). In this curative model, the MST of mice at doses of 152 
25 and 50 mg/kg were 21 and 25 days, respectively, which were significantly longer than the control 153 
(12 days). However, they were both shorter than that of chloroquine (30 days) (Table S1).  154 
 155 
 156 
 157 
Figure 2 The curative activity of mice treated with cycleanine (1) during established P. berghei 158 
infection. After infection of mice with for 3 days, cycleanine were administered at both doses of 25 159 
and 50 mg/kg, while water and chloroquinine at 5mg/ml were administered as negative and positive 160 
controls, respectively. The parasitaemia levels were monitored for a total duration of 4 days (from 161 
day 3 to day 7).  162 
 163 
2.3 In vivo metabolism of cycleanine 164 
 165 
In order to explore the in vivo metabolism of cycleanine, the plasma and urine of Wistar rats 166 
following an oral dose of 120 mg/kg body weight/day over a 24 hour period were analyzed for 167 
cycleanine metabolites. Samples from urine and plasma were prepared and submitted to high 168 
performance liquid chromatography electrospray ionization tandem mass spectrometry  169 
(HPLC-MS/MS) analysis. The peak at the retention time of 9.7 min was cycleanine (M0) with the 170 
protonated molecular ion m/z 623.3119 [M+H]+ (elemental composition C18H43N2O6) in the positive 171 
ion mode spectrum (Table 4, Figure 3 and S2). In MS/MS, the quasi-molecular ion loses a neutral 172 
molecular NH2CH3 fragment to generate an ion m/z 592.2696; also by symmetric cleavage, and 173 
breaking C-O and C-C bond to produce a fragment ion m/z 312.1594, which can also lose C2H6 to 174 
produce a fragment ion m/z 281.1165. After another C-O and C-C bond cleavage and subsequent loss 175 
of CH3 and OCH3, fragment ions m/z 204,101, 190.0857, and 159.1038 were generated. A fragment ion 176 
m/z 400.1895 was also generated by simultaneous C-O bond cleavage and C-C bond cleavage 177 
adjacent to the N atom (Figure 3, S2). 178 
 179 
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 180 
 181 
Figure 3. Possible fragmentation pattern of cycleanine. See the analysis of fragment ions in the 182 
text. 183 
 184 
Twelve peaks on LC-MS/MS chromatograms relevant to cycleanine were detected in either urine or 185 
plasma samples (Table 4, Fig. S3). The original form of cycleanine and eleven metabolites were 186 
found from the urine of rats, which were presumed to be hydroxylation (M1, M2), demethylation 187 
and hydroxylation (M3), monodemethylation (M4), didemethylation (M5), dehydrogenation and 188 
hydroxylation (M6, M12), dehydrogenation and dihydroxylation metabolite (M7) and its isomeric 189 
metabolites (M8, M9, M11). From the cycleanine-containing plasma of rats, the original form 190 
cycleanine (M0) and five metabolites were found, which were presumed to be hydroxylation (M2, 191 
M10), dehydrogenation and hydroxylation (M6, M12), dehydrogenation and dihydroxylation (M7) 192 
metabolites. Among them, the prototype (M0), hydroxylation (M1), dehydrogenation and 193 
hydroxylation (M6, M12) metabolites were detected in both rat urine and plasma (Table 4 and 194 
Supplementary materials). Therefore, the metabolic pathway of cycleanine in rat involves 195 
hydroxylation, dehydrogenation and demethylation or their combination, which are the main means 196 
of biotransformation of cycleanine to generate a large number of metabolites (M1-M12) (Fig. S5).  197 
 198 
 199 
 
          Table 4. HPLC/QTOF-MS retention times, mass spectrometric data of cycleanine and its metabolites.  200 
   201 
 No. t 
(min) 
Measured  
[M+H]+ 
m/z 
∆ppm Formula MS/MS fragment Metabolic pathways Plasma Urine 
M0 9.9 623.3125 1.41 C38H43N2O6 592.2696, 400.1895, 312.1583, 311.1508, 281.1165, 204.1011, 190.0857, 
174.0911, 159.1038 
Parent + + 
M1 7.2 639.3075 1.36 C38H43N2O7 592.2472, 416.1838, 310.1422, 220.0964, 204.1046, 190.0815, 175.0955, 
157.0901 
hydroxylation - + 
M2 7.9 639.3084 2.79 C38H43N2O7 621.2977, 416.1864, 400.1917, 327.1469, 312.1361, 220.0964, 206.0780, 
175.0988 
hydroxylation + + 
M3 8.1 625.2911 0.84 C37H41N2O7 607.2784, 425.1379, 312.1591, 298.1434, 204.0999, 190.0854, 176.0691, 
159.1033 
demethylation and 
hydroxylation 
- + 
M4 9.6 609.2956 0.96 C37H41N2O6 593.2750, 427.1577, 357.1449, 312.1580, 298.1435, 204.1020, 190.0850, 
176.0704, 145.0880 
demethylation - + 
M5 10.1 595.2799 0.73 C36H39N2O6 578.2505, 284.1282, 176.0703, 145.0879 didemethylation - + 
M6 10.4 637.2918 1.12 C38H41N2O7 328.1553, 309.1381, 202.0855, 188.0656, 157.0879 dehydrogenation and 
hydroxylation 
+ + 
M7 11.1 653.2855 0.38 C38H41N2O8 635.2754, 326.1384, 309.1381, 202.0855, 188.0656, 157.0879 dehydrogenation and 
dihydroxylation 
+ - 
M8 12.1 653.2868 1.23 C38H41N2O8 592.2459, 310.1420, 293.1154, 281.1163, 269.1169, 204.1031, 190.0884 dehydrogenation and 
dihydroxylation 
- + 
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 202 
 203 
 204 
 205 
 206 
 207 
 208 
 209 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
M9 13 653.2856 0.27 C38H41N2O8 635.2701, 400.1881, 326.1380, 310.1427, 202.0855, 173.0820, 157.0881 dehydrogenation and 
dihydroxylation 
- + 
M10 13.4 621.2966 0.97 C38H41N2O6 591.2467, 400.1893, 398.1739, 312.1572, 310.1435, 204.1013, 202.0860, 
190.0863, 188.0725, 159.1028, 157.0883 
dehydrogenation + - 
M11 13.6 653.2859 0.73 C38H41N2O8 413.1375, 324.1595, 309.1345, 281.1158, 204.1015, 159.1021 dehydrogenation and 
dihydroxylation 
+ + 
M12 14.1 637.2919 1.61 C38H41N2O7 594.2486, 414.1684, 326.1381, 312.1237, 281.1159, 218.0824, 204.1013, 
190.0874, 173.0830 
dehydrogenation and 
hydroxylation 
+ + 
 
3. Discussion 224 
Natural products (e.g. artemisinin, quinine) have demonstrated their potential as a source of 225 
antimalarial drugs. Previously, a number of BBIQ alkaloids were demonstrated to have in vitro 226 
antiplasmodial activities [16]. Cycleanine had antiplasmodial effects with IC50 of 70 nm [16] (or 80 227 
nM [17]) against P. falciparum chloroquine-sensitive clone D6 (or 3D7) and IC50 of 4.5 µM against 228 
chloroquine-resistant strain [18]. Isochondodendrine showed a low IC50 of 0.2 µM against 229 
chloroquine-resistant strain [18,19]. 2′-Norcocsuline also showed potent in vitro anti-plasmodial 230 
activity with IC50 of 48 and 248 nM against chloroquine-sensitive clone D6 (3D7) and 231 
chloroquine-resistant clone W2 [16,20], respectively (Table 1). Our results against P. falciparum 232 
chloroquine-resistant strain (Dd2) also confirmed the in vitro antimalarial activity of these 233 
compounds but with slightly higher IC50 values (Table 1) compared to the corresponding values 234 
reported in literature. Isochododendrine is a structurally demethylated analogue of cycleanine, and 235 
showed a greater potency than cycleanine in chloroquine-resistant W2 strain and the Dd2 strain in 236 
this study (Table 1). This indicated that the increase of the hydrophilicity of cycleanine could 237 
improve its antiplasmodial activity. The SI values of all three BBIQ alkaloids ranged from 14 to 133 238 
based on the KB or HTC-116 cells and W2 strain, which were much greater than those based on HOE 239 
cells and Dd2 strain. The discrepancy might be due to the different methodologies [16] used to 240 
determined IC50 or the different mammalian cancer cells or P. falciparum clones used. The 241 
semi-synthetic analogues of cycleanine (4 and 5) produced by chemical modification of cycleanine 242 
through introduction of dimethylamino- and (mono)alkynylamino- group at C-5 position exhibited 243 
increase in antiplasmodial potency and SI than cyleanine. The presence of a dimethylamino group in 244 
compound 4 could also increase the water solubility of the parent compound as often found in the 245 
modification of other natural products such as camptothecin [21] and thymoquinone [22]. 246 
Compound 5 with a unique aminoalkynyl group was used as a chemical probe for exploring the 247 
mechanism of action (e.g. cellular uptake) of cycleanine in cancer cells using click chemistry [15], and 248 
will be also be utilized for identification of the molecular target of cycleanine in parasite-infected 249 
blood cells using a chemoproteomic approach [23]. By changing the amino substitution groups, 250 
additional analogues of cycleanine with a variety of diverse structures will be synthesized for in vitro 251 
antiplasmodial evaluation. 252 
To further confirm and validate the efficacy of cycleanine (1) in vivo, its safety in healthy mice 253 
and efficacy in murine malaria model was investigated. The LD50 (4.5g/kg) of cycleanine indicated 254 
that cycleanine has a good safety profile, in agreement with a LD50 of 1.1g/kg as found previously in 255 
mice [24]. Using suppression, prophylactic and curative murine malaria models after infection with 256 
P. berghei [25], cycleanine showed a similar or closer effect at an oral dose of 50mg/kg to their positive 257 
controls (chloroquine (5 mg/kg) and pyrimethamine (1.2 mg/kg)). At least, a much higher dose of 258 
cycleanine was needed to achieve the effects of these positive controls, indicating a mild efficacy in 259 
vivo. However, its low toxicity profile could allow increase of the oral dose (e.g. 100 mg/kg), which is 260 
expected to improve its efficacy. In the curative model, the slower effect of cycleanine comparing to 261 
chloroquine might be due to the metabolism of cycleanine to various metabolites. The in vivo 262 
antimalarial activity of cycleanine was consistent with its in vitro antiplasmodial activity. To our 263 
knowledge, this is the first demonstration of the in vivo antimalarial efficacy of a BBIQ alkaloid, 264 
cycleanine. Overall, three alkaloids (1-3) of T. subcordata could contribute to the anti-malarial effects 265 
of this medicinal plant used in Nigeria for the treatment of malaria. BBIQ alkaloids of Triclisia gilletii 266 
(De Wild) Staner were also reported to be attributed to its in vitro and in vivo antimalarial activity of 267 
its plant extract [26].  268 
Study on the metabolism of drugs can further help to understand their pharmacokinetics, 269 
efficacy and safety [27]. For example, metabolites of piperaquine were shown to have stronger 270 
antiplasmodial activity [28]. However, there were only few in vivo metabolism studies of BBIQ 271 
alkaloids. Previously, in vitro metabolites of a BBIQ alkaloid, isoliensinine from the dog hepatic 272 
microsomes were identified as 2'-N-desmethylisoliensinine, 2-N-desmethyl-isoliensinine, and 273 
2'-N-6-O-didesmethylisoliensinine [29]. The study of the pharmacokinetics and metabolism of 274 
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another BBIQ alkaloid, neferinein indicated that it was partially converted to liensinine, 275 
desmethyl-liensinine, isoliensinine, and desmethyl-isoliensinine by CYP2D6 [30]. Tetrandrine was 276 
found to be initially biotransformed to a quinonemethide-derived metabolite mediated by CYP3A 277 
enzymes, which was then trapped by a glutathione to form a glutathione conjugate in mice [31]. 278 
Metabolism of isotetrandrine by in-vitro rat hepatic system produced a major metabolite, 279 
N-desmethylisotetrandrine (16%), and three minor oxidized metabolites, oxo-isotetrandrine (7%), 280 
hydroxy-isotetrandrine (6%), and oxohydroxy-isotetrandrine (7%) via N-demethylation and 281 
isoquinoline ring oxidation [32].  282 
Our identification of twelve new metabolites of cycleanine in both plasma and urine in rats 283 
using LC-MS/MS has indicated that there were various metabolic pathways of cycleanine. These 284 
metabolites of cycleanine found in rats are also likely generated in mice after the same route of oral 285 
administration, therefore they could contribute to its in vivo antimalarial efficacy found in the 286 
murine malarial model and its toxicity finding in healthy mice. Hydroxylation and demethylation of 287 
cycleanine were the common pathways consistent with those found in isoliensinine, neferinein and 288 
isotetrandrine described above. Preparation of these metabolites through chemical synthesis [33] or 289 
in vitro biotransformation using hepatic microsomes and P450 enzymes [34,35] are possible and 290 
necessary to evaluate their potency and toxicity. Such information can be used to further guide 291 
chemical design and modification of cycleanine to improve its potency, pharmacokinetics and 292 
increasing metabolic stability [36]. Further work is necessary and on-going in our laboratory to 293 
determine the in vivo antimalarial effects of BBIQ alkaloids (2, 3), semi-synthetic derivatives (4, 5), in 294 
vitro and/or in vivo antimalarial activity of the metabolites (M1-12) of cycleanine. Novel active drugs 295 
particularly those with a wide safety margin are required to help alleviate malaria morbidity and 296 
mortality, and to contribute to the global control of malaria and infectious diseases.  297 
4. Materials and Methods  298 
4.1 Chemicals 299 
Chloroquine and pyrimethamine were sourced from Sigma-Aldrich. Cycleanine (1) [13], and 300 
two minor alkaloids, isochondodendrine (2) and 2′-norcocsuline (3) were isolated from Triclisia 301 
subcordata [14]. Compound 4 and 5 (Figure 1) were previously prepared from cycleanine (1) [15]. 302 
 303 
4.2 In vitro anti-plasmodial activity  304 
The evaluation of in vitro antiplasmodial activity of the alkaloids (1-3) and semisynthetic 305 
analogues (4 and 5) were performed on the intraerythrocytic P. falciparum Dd2 strain (chloroquine 306 
resistant strain) using a SYBR Green1 Fluorescence dye assay as described [22,37,38]. Compounds 307 
1-5 were prepared in DMSO with no greater than 1% of the total solvent concentration in any assay. 308 
Normalized fluorescence signals were measured against controls with 1% DMSO (100% growth) and 309 
after exposure to a supralethal concentration (10 µM) of chloroquine (0% growth). Determination of 310 
the 50% inhibitory concentration (IC50) was performed form a Log concentration versus mean 311 
normalized fluorescence signal curve using GraphPad Prism software (v5.0). Each biological 312 
replicate consisted of three technical repeats, with three independent biological replicates 313 
performed. 314 
 315 
4.3 Evaluation of the in vivo antimalarial activity of cycleanine 316 
Malaria parasite 317 
Chloroquine-sensitive strain of P. berghei were sourced from the National Institute of Medical 318 
Research (NIMER), Yaba Lagos, Nigeria and maintained by sub-passage in mice.  319 
Parasite inoculation 320 
Each mouse was inoculated intraperitoneally with about 1 x 107 P. berghei parasitized 321 
erythrocytes in 0.2 mL of infected blood (5 x 107 P. berghei erythrocytes/mL) according to published 322 
procedure [39]. 323 
Experimental animals 324 
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Female and male Swiss albino mice (18-25 g) were obtained from the University of Uyo’s 325 
animal house. Before use mice were kept in cages and acclimatized for 10 days. All mice were kept in 326 
cross ventilated rooms at room temperature. The care and use of mice were performed in accordance 327 
with the National Institute of Health Guide for the Care and Use of laboratory Animals (NIH 328 
Publication, 1996). This investigation was approved from the University of Uyo’s Animal Ethics 329 
Committee. 330 
Determination of median lethal dose (LD50) of cycleanine 331 
The median lethal dose (LD50) of cycleanine was determined using albino mice by 332 
intraperitoneal (i.p) route [40]. Different doses of cycleanine (10 – 5000 mg/kg) were intraperitoneally 333 
administrated to groups of three mice each. The mice were monitored for manifestation of physical 334 
signs of toxicity including decrease of motor activity, writhing, decrease of body/limb tone, and 335 
weakness and death. The number of deaths in each group within 24 h was recorded. The LD50 value 336 
was calculated as geometrical means of the minimum dose producing 100% mortality and the 337 
maximum dose producing 0%.  338 
Drug administration 339 
Cycleanine, chloroquine and pyrimethamine were prepared in water and administered orally 340 
with the aid of a stainless metallic feeding cannula. 341 
Suppressive activity of cycleanine  342 
The schizontocidal activity of the cycleanine and chloroquine against early P. berghei infection in 343 
mice was measured according to an established protocol [25,41,42]. On the first day, twenty-four 344 
mice were infected with the parasite and randomly separated into four groups. The mice in group 1 345 
and 2 were given 25 and 50 mg/kg of cycleanine respectively, group 3 was given 5 mg/kg of 346 
chloroquine (positive control) and group 4 given distilled water (10 mL/kg, negative control) for four 347 
consecutive days. Thin films were made from the tail blood on the fifth day. Parasitized erythrocytes 348 
were counted in stained films (by Giemsa stain) under a microscope. The average suppression of 349 
parasitemia (%) was calculated as follows:  350 
 * 100 351 
The MST (days) of the mice in each group was determined over a period of 30 days. 352 
Prophylactic activity of cycleanine 353 
The prophylactic activity of cycleanine was evaluated using the method as previously described 354 
[42,43]. The mice were randomly divided into four groups of six mice per group. Groups 1 and 2 355 
were given 25 and 50 mg/kg of cycleanine respectively, group 3 was given 1.2 mg/kg of 356 
pyrimethamine (positive control) and group 4 given 10 mL/kg of distilled water (negative control). 357 
Administration of the cycleanine and drug continued for three consecutive days. On the fourth day, 358 
the mice were inoculated with P. berghei. The parasitemia level was evaluated by blood smears after 359 
3 days. The survival time (day) of the mice were recorded over a period of 30 days and MST were 360 
calculated. 361 
Curative activity of cycleanine 362 
The curative activity of cycleanine was assessed according to the method described previously 363 
[42,44]. P. berghei was injected intraperitoneally into another twenty-four mice on the first day. Three 364 
days later, the mice were also separated into four groups of six mice per group. Groups 1 and 2 were 365 
administered different doses of cycleanine, 25 and 50 mg/kg respectively, group 3 was given 5 366 
mg/kg chloroquine (positive control) and group 4 was given 10 mL/kg distilled water (negative 367 
control). Cycleanine and chloroquine were given once a day for 5 days. Mice tail blood samples were 368 
collected on each day, and Giemsa stained thin smears were prepared to determine the parasitemia 369 
level. The MST of the mice in each group was determined over a period of 30 days. 370 
 371 
4.4 Metabolism of cycleanine in rats  372 
High-performance liquid chromatography quadrupole time-of-flight mass spectrometry 373 
(HPLC-Q-TOF-MS/MS)  374 
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Analysis of cycleanine metabolites was performed through HPLC-Q-TOF-MS/MS system that 375 
consists of an Agilent 1260 HPLC coupled with Agilent 6530 Q-TOF mass spectrometer with dual 376 
Agilent Jet Stream electrospray ionization source (Agilent Technologies, CA, USA). The mass spectra 377 
were recorded in positive Auto MS/MS mode and the parameters were set as follows: temperature of 378 
drying and sheath gas, 300 °C and 350 °C; skimmer, 75 V; capillary voltage, 4000 V; fragmentor, 110 379 
V; nozzle voltage, 1000 V; collision energy, 50 eV; pressure of nebulizer, 35 psi; and flow rate of the 380 
drying and sheath gas, 5 and 11 L/min, respectively. The Q-TOF mass spectra were recorded in 381 
high-resolution mode. The range of mass-to-charge ratio (m/z) scanning was set between 100 and 382 
1200. Samples (5 µL) were loaded onto an Agilent Poroshell 120 EC-C18 column (100×2.1 mm, 2.7 383 
µm) at 35 °C. The mobile phase consisted of water containing 0.1 % formic acid (solvent A) and 384 
acetonitrile containing 0.1% formic acid (solvent B) at a flow rate of 0.35 mL/min. Gradient 385 
separation was achieved by changing the proportion of the solvent B mobile phase as follows: 0- 2 386 
min, 10% B; 2.1- 5 min, 18%- 20% B; 30- 45 min, 70%- 90% B; and 45- 50 min, 10% B. Mass hunter 387 
Workstation software (Agilent Technologies, Palo Alto, CA, USA) was utilized for the system 388 
operation and data analysis.  389 
In vivo animal experiments  390 
In vivo animal experiments were approved by the Animal Ethics Committee of Shanghai 391 
Institute of Materia Medica, and performed according to procedures approved by the Institutional 392 
Animal Care and Use Committee of Shanghai Institute of Materia Medica, Chinese Academy of 393 
Science. Male Wistar rats were obtained from Shanghai SLAC Laboratory Animal Co., Ltd. 394 
(Shanghai, China). The rats were given free access to water and standard diet under controlled 395 
humidity (45%–55%) and temperature (20 °C–24 °C), and except in the overnight fasting period 396 
before administration of cycleanine. The rats were adapted to the environment for a week. 397 
Cycleanine (1) was suspended in 0.4% carboxymethyl cellulose sodium (CMC-Na) and was 398 
formulated at 12 mg/mL for intragastric administration to Wistar rats (male, 220 ± 10 g, fasted for 12 399 
hours prior to administration) at a dose of 120 mg/kg body weight. Three rats were used for blood 400 
collection through orbital vein using cannulation at 0, 0.5, 1, 2, 4, 6, 8, 12 and 24h post dose after 401 
anaesthetization with isoflurane. The plasma samples were separated from blood by centrifugation 402 
at 12000 rpm and 4 °C for 10 min. Another three rats were placed in the metabolism cages, and urine 403 
samples were collected into tubes from 0 to 24 h after oral administration of cycleanine. All samples 404 
were stored in a -80 °C freezer before analysis. Total of 1.2 mL of plasma or urine sample was mixed 405 
with 3 times the volume of acetonitrile to precipitate proteins. After centrifugation at 14,000 rpm for 406 
10 min, the supernatant was collected and evaporated under vacuum. The residue was reconstituted 407 
in 200 µL methanol, and 5 µL of each sample was injected into HPLC-Q-TOF-MS/MS analysis.  408 
4.5 Statistical Analysis 409 
Data was expressed as mean ± standard error of mean (SEM). Data was subjected to GraphPad 410 
Prism software analysis. Results were analyzed using one-way analysis of variance (ANOVA) 411 
followed by a post Tukey-Kramer multiple comparison test. The difference between mean of the 412 
experimental and control groups was considered significant at p < 0.05 (ANOVA).  413 
5. Conclusions 414 
Three BBIQ alkaloids – cycleanine (1), isochondodendrine (2) and 2′-norcocsuline (3) of T. subcordata 415 
and two semi-synthetic analogues (4 and 5) of cycleanine were demonstrated to exert significant in 416 
vitro antiplasmodial activities against P. falciparum. Cycleanine (1) was further demonstrated to have 417 
safety and efficacy in the treatment of mice infected with P. berghei. Cycleanine was transformed to 418 
various metabolites in rats after oral delivery. The findings from this study support the use of T. 419 
subcordata as antimalarial agent in traditional medicine. BBIQ alkaloids could be exploited in novel 420 
drug development in search of antimalarial agents/drugs urgently needed to challenge resistant 421 
plasmodium species which currently present significant great threat to human life.  422 
Supplemental Materials: Figure S1: Dose-response antiplasmodial curves of BBIQ alkaloids (1-5); Figure S2: 423 
HPLC ESI-MS/MS spectrum of cycleanine; Figure S3: Extracted ion chromatograms of cycleanine (M0), its 5 424 
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metabolites (M2, M6, M7, M10 and M12) in plasma, 11 metabolites (M1-6, M7-9, M11-12) in urine of rat. M0 and 425 
M1, M6, and M12 were present in both urine and plasma. Figure S4: MS/MS spectra of cycleanine metabolites 426 
(M1-12). Figure S5: Possible metabolic pathway of cycleanine in rats. Table S1: Curative activity and mean 427 
survival time (MST) of mice treated with cycleanine (1) during established P. berghei infection.  428 
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